"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • For Professionals
  • FDA Approvals
  • FDA grants accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY) for patients with hepatocellular carcinoma (HCC)

FDA grants accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY) for patients with hepatocellular carcinoma (HCC)

11 Mar 2020 4:11 PM | Anonymous

The U.S. Food and Drug Administration granted accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY, Bristol-Myers Squibb Co.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software